Table 3.
Multivariate analyses demonstrating the role of baseline fibrosis stage (A) and high residual fibrosis (B) in arrhythmia recurrence.
| HAZARD RATIO | P VALUE | 95% CI | |
|---|---|---|---|
| A | |||
| Stage I | – | ||
| Stage II | 3.6 | 0.001 | 1.64–7.82 |
| Stage III | 5.2 | <0.001 | 2.23–10.76 |
| Stage IV | 6.2 | 0.001 | 1.70–17.48 |
| # PVA encircled | 1.02 | 0.77 | 0.85–1.27 |
| Persistent AF | 1.38 | 0.26 | 0.79–2.44 |
| Hypertension | 0.98 | 0.96 | 0.59–1.86 |
| Diabetes | 1.15 | 0.69 | 0.59–2.30 |
| Congestive HF | 0.63 | 0.34 | 0.25–1.68 |
| B | |||
| High Residual | 3.3 | <0.001 | 1.75–5.59 |
| # PVA encircled | 1.01 | 0.94 | 0.84–1.25 |
| Persistent AF | 1.54 | 0.11 | 0.90–2.64 |
| Hypertension | 1.04 | 0.90 | 0.62–1.92 |
| Diabetes | 1.12 | 0.73 | 0.58–2.21 |
| Congestive HF | 0.59 | 0.28 | 0.24–1.56 |